239 related articles for article (PubMed ID: 20568894)
21. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
[TBL] [Abstract][Full Text] [Related]
22. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
Kang Z; Jänne OA; Palvimo JJ
Mol Endocrinol; 2004 Nov; 18(11):2633-48. PubMed ID: 15308689
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic modulation of AR gene expression in prostate cancer DU145 cells with the combination of sodium butyrate and 5'-Aza-2'-deoxycytidine.
Fialova B; Luzna P; Gursky J; Langova K; Kolar Z; Trtkova KS
Oncol Rep; 2016 Oct; 36(4):2365-74. PubMed ID: 27499010
[TBL] [Abstract][Full Text] [Related]
24. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate.
Sekhavat A; Sun JM; Davie JR
Biochem Cell Biol; 2007 Dec; 85(6):751-8. PubMed ID: 18059533
[TBL] [Abstract][Full Text] [Related]
25. Characterization of receptor interaction and transcriptional repression by the corepressor SMRT.
Li H; Leo C; Schroen DJ; Chen JD
Mol Endocrinol; 1997 Dec; 11(13):2025-37. PubMed ID: 9415406
[TBL] [Abstract][Full Text] [Related]
26. The co-regulators SRC-1 and SMRT are involved in interleukin-6-induced androgen receptor activation.
Wang Q; Wang H; Ju Q; Ding Z; Ge X; Shi QM; Zhou JL; Zhou XL; Zhang JP; Zhang MR; Yu HM; Xu LC
Eur Cytokine Netw; 2016 Nov; 27(4):108-113. PubMed ID: 28396297
[TBL] [Abstract][Full Text] [Related]
27. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells.
Liu P; Li S; Gan L; Kao TP; Huang H
Cancer Res; 2008 Dec; 68(24):10290-9. PubMed ID: 19074897
[TBL] [Abstract][Full Text] [Related]
28. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity.
Peterson TJ; Karmakar S; Pace MC; Gao T; Smith CL
Mol Cell Biol; 2007 Sep; 27(17):5933-48. PubMed ID: 17591692
[TBL] [Abstract][Full Text] [Related]
29. Exchange of a nuclear corepressor between NF-kappaB and CREB mediates inhibition of phosphoenolpyruvate carboxykinase transcription by NF-kappaB.
Yan JH; Gao ZG; Ye JP; Weng JP
Chin Med J (Engl); 2010 Jan; 123(2):221-6. PubMed ID: 20137375
[TBL] [Abstract][Full Text] [Related]
30. A designed cell-permeable aptamer-based corepressor peptide is highly specific for the androgen receptor and inhibits prostate cancer cell growth in a vector-free mode.
Reeb CA; Gerlach C; Heinssmann M; Prade I; Ceraline J; Roediger J; Roell D; Baniahmad A
Endocrinology; 2011 Jun; 152(6):2174-83. PubMed ID: 21486935
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
[TBL] [Abstract][Full Text] [Related]
32. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha.
Ko S; Shi L; Kim S; Song CS; Chatterjee B
Mol Endocrinol; 2008 Feb; 22(2):273-86. PubMed ID: 17975021
[TBL] [Abstract][Full Text] [Related]
33. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP.
Sato N; Sadar MD; Bruchovsky N; Saatcioglu F; Rennie PS; Sato S; Lange PH; Gleave ME
J Biol Chem; 1997 Jul; 272(28):17485-94. PubMed ID: 9211894
[TBL] [Abstract][Full Text] [Related]
34. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.
Cinar B; Yeung F; Konaka H; Mayo MW; Freeman MR; Zhau HE; Chung LW
Biochem J; 2004 Apr; 379(Pt 2):421-31. PubMed ID: 14715080
[TBL] [Abstract][Full Text] [Related]
35. Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.
Buchanan G; Need EF; Barrett JM; Bianco-Miotto T; Thompson VC; Butler LM; Marshall VR; Tilley WD; Coetzee GA
Mol Cell Endocrinol; 2011 Aug; 342(1-2):20-31. PubMed ID: 21664238
[TBL] [Abstract][Full Text] [Related]
36. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
[TBL] [Abstract][Full Text] [Related]
37. p,p'-Dichlorodiphenyltrichloroethane (p,p'-DDT) and p,p'-dichlorodiphenyldichloroethylene (p,p'-DDE) repress prostate specific antigen levels in human prostate cancer cell lines.
Wong LI; Labrecque MP; Ibuki N; Cox ME; Elliott JE; Beischlag TV
Chem Biol Interact; 2015 Mar; 230():40-9. PubMed ID: 25682698
[TBL] [Abstract][Full Text] [Related]
38. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
39. GR SUMOylation and formation of an SUMO-SMRT/NCoR1-HDAC3 repressing complex is mandatory for GC-induced IR nGRE-mediated transrepression.
Hua G; Paulen L; Chambon P
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E626-34. PubMed ID: 26712002
[TBL] [Abstract][Full Text] [Related]
40. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
Chen L; Meng S; Wang H; Bali P; Bai W; Li B; Atadja P; Bhalla KN; Wu J
Mol Cancer Ther; 2005 Sep; 4(9):1311-9. PubMed ID: 16170022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
